Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst consensus: Six brokerages rate Immix Biopharma a "Moderate Buy" (4 buys, 1 hold, 1 sell) with an average 12‑month price target of $18.25, and recent upgrades include Mizuho and HC Wainwright raising targets to $15 while Citizens Jmp set $23.
• Business and results: The company is a clinical‑stage immuno‑oncology firm (lead candidate IMX‑110) that missed quarterly EPS (‑$0.28 vs. ‑$0.16 est.), analysts forecast ~‑$0.87 EPS for the year, and the stock trades around $8.94 with a market cap near $474M.

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $18.25.

Several analysts recently commented on IMMX shares. Mizuho increased their price objective on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an "outperform" rating in a research report on Monday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Immix Biopharma from a "hold" rating to a "sell" rating in a research note on Sunday, March 15th. HC Wainwright increased their price target on shares of Immix Biopharma from $12.00 to $15.00 and gave the company a "buy" rating in a report on Friday, March 27th. Finally, Citizens Jmp reissued a "market outperform" rating and set a $23.00 price target on shares of Immix Biopharma in a research report on Friday, March 27th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Kera Capital Partners Inc. purchased a new stake in shares of Immix Biopharma during the fourth quarter valued at $68,000. Virtu Financial LLC purchased a new position in Immix Biopharma in the 4th quarter worth about $386,000. KVP Capital Advisors LP purchased a new position in Immix Biopharma in the 4th quarter worth about $1,205,000. XTX Topco Ltd lifted its stake in Immix Biopharma by 32.0% during the 4th quarter. XTX Topco Ltd now owns 46,394 shares of the company's stock valued at $243,000 after acquiring an additional 11,241 shares during the period. Finally, Quadrature Capital Ltd bought a new position in Immix Biopharma during the 4th quarter valued at about $116,000. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Trading Up 3.7%

Immix Biopharma stock opened at $8.94 on Friday. Immix Biopharma has a 12 month low of $1.34 and a 12 month high of $11.61. The company has a market capitalization of $473.55 million, a price-to-earnings ratio of -10.04 and a beta of 0.20. The business's fifty day simple moving average is $8.09 and its two-hundred day simple moving average is $5.43.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.12). On average, equities research analysts predict that Immix Biopharma will post -0.87 EPS for the current year.

Immix Biopharma Company Profile

Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.